Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biosidus, the most common co-covered peer. We currently track 1 Cross-Sector story that mention epoetin alfa, all published on July 27, 2026.
1 verified story tracked
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biosidus, the most common co-covered peer. We currently track 1 Cross-Sector story that mention epoetin alfa, all published on July 27, 2026. Each carries 1 original source on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering epoetin alfa. Shared-story counts are live from our verified record — not editorial picks.
Biosidus, a Latin American biotech, signed a licensing deal with Mubadala Bio at BIO 2026 to introduce four biologic therapies—including epoetin alfa and filgrastim—into the UAE via DiabTec. The move advances local pharma manufacturing and expands Biosidus' global footprint.
Source: prnewswire.com
